My top three takeaways from the 2020 San Antonio Breast Cancer Symposium.
There were some noteworthy developments this year in targeted therapies for hormone receptor-positive breast cancer.
Findings from the TAILORx clinical trial will help personalize treatment decisions for many patients with early stage breast cancer.
New clinical trials will test whether the addition of progesterone could improve treatment for hormone receptor-positive breast cancer.
Cancer research stories worth following this summer include reports from ASCO on a web app that improves survival for lung cancer patients and a “biosimilar” treatment for the breast cancer drug Herceptin.
Research findings presented at the 2015 San Antonio Breast Cancer Symposium may preview an era in which breast cancer treatments will be tailored to each patient.
New discoveries about the role of the hormone progesterone in breast cancer could potentially lead to improved treatment options for many breast cancer patients.